-$1.01 Earnings Per Share Expected for Clovis Oncology (NASDAQ:CLVS) This Quarter

Share on StockTwits

Wall Street brokerages expect Clovis Oncology (NASDAQ:CLVS) to announce ($1.01) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Clovis Oncology’s earnings. The lowest EPS estimate is ($1.11) and the highest is ($0.88). Clovis Oncology posted earnings of ($1.89) per share during the same quarter last year, which indicates a positive year over year growth rate of 46.6%. The business is scheduled to announce its next quarterly earnings results on Thursday, November 5th.

On average, analysts expect that Clovis Oncology will report full-year earnings of ($4.38) per share for the current fiscal year, with EPS estimates ranging from ($4.69) to ($4.18). For the next year, analysts anticipate that the firm will post earnings of ($2.54) per share, with EPS estimates ranging from ($3.36) to ($1.59). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Clovis Oncology.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.11). The business had revenue of $39.89 million for the quarter, compared to analysts’ expectations of $44.65 million.

Several equities research analysts have weighed in on CLVS shares. HC Wainwright reiterated a “buy” rating and issued a $23.00 target price on shares of Clovis Oncology in a report on Monday, September 21st. ValuEngine lowered shares of Clovis Oncology from a “buy” rating to a “hold” rating in a report on Wednesday, September 16th. Finally, BidaskClub upgraded shares of Clovis Oncology from a “sell” rating to a “hold” rating in a report on Saturday, September 19th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company’s stock. Clovis Oncology currently has an average rating of “Hold” and a consensus target price of $9.64.

Several large investors have recently modified their holdings of CLVS. Great West Life Assurance Co. Can acquired a new stake in shares of Clovis Oncology during the second quarter worth $32,000. Private Advisor Group LLC acquired a new stake in shares of Clovis Oncology during the second quarter worth $35,000. Canada Pension Plan Investment Board acquired a new stake in shares of Clovis Oncology during the second quarter worth $41,000. Ameritas Investment Partners Inc. raised its holdings in shares of Clovis Oncology by 61.0% during the second quarter. Ameritas Investment Partners Inc. now owns 6,387 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 2,420 shares during the period. Finally, Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Clovis Oncology during the first quarter worth $72,000. Institutional investors and hedge funds own 52.80% of the company’s stock.

CLVS traded down $0.17 during mid-day trading on Monday, hitting $5.75. The stock had a trading volume of 2,592,060 shares, compared to its average volume of 5,249,263. The stock’s fifty day simple moving average is $5.74 and its 200-day simple moving average is $6.58. The firm has a market capitalization of $507.15 million, a price-to-earnings ratio of -0.95 and a beta of 2.26. Clovis Oncology has a 1-year low of $2.93 and a 1-year high of $17.37.

About Clovis Oncology

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Read More: What are catch-up contributions?

Get a free copy of the Zacks research report on Clovis Oncology (CLVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply